Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $67M | $-276M | $-279M | $-71M | -160.0% | 25.2% | 60.2% |
| 2024 | $54M | $-169M | $-174M | $134M | -42.1% | - | 14.0% |
| 2023 | $0M | $-150M | $-153M | $-125M | -38.4% | - | 12.4% |
| 2022 | $0M | $-135M | $-136M | $-111M | -32.3% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 67.48 |
| Operating Revenue | 67.48 |
| Cost Of Revenue | 0.06 |
| Gross Profit | 67.42 |
| Operating Expense | 371.06 |
| Research And Development | 251.07 |
| Selling General And Administration | 119.98 |
| Total Expenses | 371.11 |
| Operating Income | -303.63 |
| Total Operating Income As Reported | -303.63 |
| EBITDA | -275.82 |
| Normalized EBITDA | -275.82 |
| EBIT | -276.86 |
| Interest Income | 26.77 |
| Interest Expense | 1.51 |
| Net Interest Income | 25.26 |
| Interest Income Non Operating | 26.77 |
| Interest Expense Non Operating | 1.51 |
| Net Non Operating Interest Income Expense | 25.26 |
| Pretax Income | -278.37 |
| Tax Provision | 0.30 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -278.67 |
| Net Income From Continuing And Discontinued Operation | -278.67 |
| Net Income From Continuing Operation Net Minority Interest | -278.67 |
| Net Income | -278.67 |
| Net Income Common Stockholders | -278.67 |
| Net Income Including Noncontrolling Interests | -278.67 |
| Normalized Income | -278.67 |
| Diluted NI Availto Com Stockholders | -278.67 |
| Basic Average Shares | 87.68 |
| Diluted Average Shares | 87.68 |
| Reconciled Depreciation | 1.03 |
| Reconciled Cost Of Revenue | 0.06 |
| General And Administrative Expense | 119.98 |
| Other Gand A | 119.98 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Kura Oncology, Inc.this co. | KURA | $779M | - | 4.47 | -160.0% | - |
| Replimune Group, Inc. | REPL | $815M | -3.30 | 1.96 | -59.5% | -3.31 |
| Esperion Therapeutics, Inc. | ESPR | $806M | - | - | 7.5% | 13.94 |
| Lumexa Imaging Holdings, Inc. | LMRI | $792M | -16.81 | 1.35 | -8.0% | 11.96 |
| Eton Pharmaceuticals, Inc. | ETON | $792M |
| - |
| - |
| - |
| - |
| -172.06 |
| 30.27 |
| -17.6% |
| 248.97 |
| Phathom Pharmaceuticals, Inc. | PHAT | $786M | -3.55 | -1.79 | 50.5% | -5.69 |
| Geron Corporation | GERN | $776M | -9.30 | 3.44 | -37.0% | -16.53 |
| BioAge Labs, Inc. | BIOA | $757M | -9.39 | 2.78 | -29.6% | -7.19 |
| EVMN | EVMN | $745M | -10.82 | 3.63 | -33.5% | -8.82 |
| Peer Median | - | -9.39 | 2.78 | -23.6% | -4.50 | |